Based on the key indicators related to Theriva Biologics' liquidity, profitability, solvency, and operating efficiency, Theriva Biologics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, Theriva Biologics' Other Current Liabilities is fairly stable compared to the past year. Property Plant And Equipment Net is likely to rise to about 2.6 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 4.2 M in 2025. Key indicators impacting Theriva Biologics' financial strength include:
The essential information of the day-to-day investment outlook for Theriva Biologics includes many different criteria found on its balance sheet. An individual investor should monitor Theriva Biologics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Theriva Biologics.
Please note, the imprecision that can be found in Theriva Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Theriva Biologics. Check Theriva Biologics' Beneish M Score to see the likelihood of Theriva Biologics' management manipulating its earnings.
Theriva Biologics Stock Summary
Theriva Biologics competes with Avalo Therapeutics, Virpax Pharmaceuticals, Revelation Biosciences, Biodexa Pharmaceticals, and Praxis Precision. Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. Theriva Biologics Inc. is headquartered in Rockville, Maryland. Theriva Biologics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 16 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Theriva Biologics. It measures of how well Theriva is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Theriva Biologics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Theriva had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Theriva Biologics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Theriva Biologics's current stock value. Our valuation model uses many indicators to compare Theriva Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Theriva Biologics competition to find correlations between indicators driving Theriva Biologics's intrinsic value. More Info.
Theriva Biologics is rated fifth in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, Theriva Biologics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Theriva Biologics' earnings, one of the primary drivers of an investment's value.
Theriva Biologics Systematic Risk
Theriva Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Theriva Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Theriva Biologics correlated with the market. If Beta is less than 0 Theriva Biologics generally moves in the opposite direction as compared to the market. If Theriva Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Theriva Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Theriva Biologics is generally in the same direction as the market. If Beta > 1 Theriva Biologics moves generally in the same direction as, but more than the movement of the benchmark.
Theriva Biologics Thematic Clasifications
Theriva Biologics is part of several thematic ideas from Computers to IT. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Theriva Biologics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Theriva Biologics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Theriva Biologics growth as a starting point in their analysis.
Theriva Biologics January 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Theriva Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Theriva Biologics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Theriva Biologics based on widely used predictive technical indicators. In general, we focus on analyzing Theriva Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Theriva Biologics's daily price indicators and compare them against related drivers.
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.